IP Library Granted Patent US 12,498,374
Granted Patent B2
US 12,498,374 · App. 18/596,432 · Granted Dec 16, 2025

Method for manufacturing a patient specific cell population using a multifunctional self-contained apparatus and tubing set

Inventors: Stefan Miltenyi (Bergisch Gladbach, DE); Winfried Schimmelpfennig (Krakow am See, DE); Holger Lantow (Rostock, DE); Niklas Elmar Neuschaefer (Rostock, DE); Martin Biehl (St. Wendel, DE); Eiad Kabaha (Bonn, DE); Juergen Schulz (Jesteburg, DE)
Assignee: MILTENYI BIOTEC B.V. & CO. KG
G01N33/58A61K40/11A61K40/19A61K40/22A61K40/24A61K40/416A61K40/418A61K40/42A61K40/46A61M1/0209A61M1/3618A61M1/3633A61M1/3679A61M1/3692A61M1/3693A61M1/3696B01D15/3809B01D15/3885B01D21/26B03C1/002B03C1/027B03C1/032B03C1/0332B03C1/0335B03C1/034B03C1/288B04B1/12B04B5/00B04B5/04B04B5/0442B04B5/10B04B7/08B04B13/00C12M23/28C12M33/10C12M41/48C12M47/04C12N5/0018C12N5/0636C12N5/0646C12N5/0647C12N5/0669G01N35/0098A61M1/3623A61M2202/0071A61M2202/0413A61M2202/0427A61M2202/10B01D21/262B01L3/5021B03C2201/18B03C2201/26B04B2005/0464B04B2013/006C12N2500/34C12N2501/998G01N2333/70596
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,498,374
App. No.
18/596,432
Granted
Dec 16, 2025
Kind
B2
Abstract

The invention relates to a system, comprising: a) a sample processing unit, comprising an input port and an output port coupled to a rotating container having at least one sample chamber, the sample processing unit configured provide a first processing step to a sample or to rotate the container so as to apply a centrifugal force to a sample deposited in the chamber and separate at least a first component and a second component of the deposited sample; and b) a sample separation unit coupled to the output port of the sample processing unit, the cell separation unit comprising separation column holder, a pump and a plurality of valves configured to at least partially control fluid flow through a fluid circuitry and a separation column positioned in the holder, the separation column configured to separate labeled and unlabeled components of sample flowed through the column.

Claims (60)

1 . A method of preparing a therapeutic cell population from a population of donor cells for administration to a patient in need thereof, the method comprising:

reversibly installing a single-use assembly on a computer controlled apparatus;

wherein the single-use assembly is closed and sterile, and is thereby configured to prepare said therapeutic cell population from a donor cell population in a manner such that the therapeutic cell population is suitable for administration to a human patient;

wherein the single-use assembly includes the following components:

(1) a sample processing unit that includes an input port operably connected to a sample chamber, wherein the sample chamber comprises ports to supply fresh media and gasses to support culture of a sample of cells in the chamber, and is configured to wash target cells and/or adjust sample volume as needed,

(2) a sample separation unit that includes a magnetic separation member, and

(3) fluid circuitry that interconnects the sample processing unit and the sample separation unit, so that cells can be caused to flow between the sample processing unit and the sample separation unit in either direction;

wherein the computer controlled apparatus is configured to operate the sample processing unit, the sample separation unit, and the fluid circuitry of the single-use assembly in a sequence of steps chosen by an operator;

programming or operating the computer-controlled apparatus to process a population of donor cells in the single-use assembly to produce the therapeutic cell population by applying a plurality of steps selected from the following steps (a) to (e):

(a) positive or negative selection of a defined population of target cells using the magnetic separation member;

(b) activation or differentiation of cells by culturing with one or more cytokines or growth factors;

(c) transduction or transfection of cells by culturing with genetic material;

(d) expansion of cells before or after any of steps (a) to (c) by culturing in fresh media; and

(e) formulation of the therapeutic cell population in an adjusted volume of fresh liquid.

2 . The method of claim 1 , wherein the magnetic separation member is configured so that magnetically responsive particles or microparticles coated with monoclonal antibody specific for cell surface antigens can be used to select chosen cell populations.

3 . The method of claim 1 , wherein the magnetic separation member comprises an electromagnet that can be operated to retain or release magnetically labeled target cells.

4 . The method of claim 1 , wherein the sample separation unit is configured for positive selection of target cells,

whereby target cells labeled with magnetic particles are retained in the magnetic separation member, while non-target cells that are not labeled with magnetic particles pass into a waste container.

5 . The method of claim 1 , wherein the sample separation unit is configured for negative selection of target cells,

whereby non-target cells labeled with magnetic particles are retained in the magnetic separation member and discarded, while target cells that are not labeled with magnetic particles are retained.

6 . The method of claim 1 , wherein the components of the single-use assembly are constructed and arranged so that target cells can be isolated from other cells in the donor cell population by multiple loops of positive and negative selection using the magnetic separation member.

7 . The method of claim 1 , wherein the sample chamber is configured so that a cell population may be cultured therein for a sufficient time and under suitable conditions whereby the cell population is expanded.

8 . The method of claim 1 , wherein the transduction or transfection in step (c) is done by electroporation.

9 . The method of claim 1 , wherein the sample chamber comprises a window or prism through which to monitor cells in the sample chamber.

10 . The method of claim 1 , wherein the sample processing unit is configured to remove red cells and/or platelets before processing the donor cell population using the sample separation unit.

11 . The method of claim 1 , wherein the sample processing unit is configured to separate different cell populations by gradient centrifugation.

12 . The method of claim 11 , wherein the computer controlled apparatus comprises a holder for the magnetic separation member, a pump operating on the fluid circuitry, and a plurality of valves that control flow through the fluid circuitry and the magnetic separation member of the single-use assembly.

13 . The method of claim 1 , wherein the computer controls the flow of fluids through the fluid circuitry and sample separation unit, controls magnetic field strength in the sample separation unit to provide for retention and release of magnetically labeled target cells or analyte, and directs final collection products into appropriate containers.

14 . The method of claim 1 , wherein the computer is programmed to operate the apparatus to prepare a genetically modified cell population from a donor cell population in the single-use assembly by performing the following steps:

(a) receive a sample of cells through the input port into the sample processing unit;

(b) prepare the sample of cells in the sample processing unit;

(c) transfer the prepared cells from the sample processing unit to the sample separation unit;

(d) separate the prepared cells into target cells and non-target cells in the sample separation unit using the magnetic separation member, allowing non-target cells to pass to a waste container,

(e) transfer the separated target cells back to the sample processing unit;

(f) combine and culture the target cells with genetic material in the sample chamber, supplying gas and fresh media as needed so as to genetically modify the cells;

(g) process the genetically modified cells by washing and adjusting volume; and thereafter

(h) deliver the genetically modified cells as a therapeutic cell population to a product collection container.

15 . The method of claim 1 , wherein cells in the population of donor cells are autologous or allogeneic to the patient.

16 . The method of claim 1 , wherein the therapeutic cell population has been enriched for cells that have one or more of the following characteristics:

CD34 positive,

CD133 positive,

CD14 positive, and/or

CD8 negative.

17 . The method of claim 1 , wherein the therapeutic cell population is either:

a population of stem cells or progenitor grafts from cord blood;

a dendritic cell vaccine;

activated natural killer cells;

peripheral blood mononuclear cells;

an expanded population of T helper cells, or a population of antigen-specific T cells.

18 . The method of claim 1 , wherein the therapeutic cell population obtained thereby is genetically modified.

19 . A method of therapy of a human patient in need thereof, comprising:

obtaining a therapeutic cell population from a population of donor cells that have been prepared according to the method of claim 1 , and

administering the therapeutic cell population to the patient.

20 . The method of claim 19 , wherein the therapy is in the context of one of the following:

stem cell or progenitor cell transplantation for tissue regeneration,

cancer treatment,

treatment of an infectious disease,

tissue regeneration,

inducing immunological tolerance for the purpose of organ transplantation, or

inducing immunological tolerance for therapeutic management of an autoimmune disease.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2025
From: MILTENYI BIOTEC GMBH
To: MILTENYI BIOTEC B.V. & CO. KG
Reel/Frame 071889/0562 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2024
From: MILTENYI, STEFAN; SCHIMMELPFENNIG, WINFRIED; LANTOW, HOLGER; KABAHA, EIAD; NEUSCHAFER, ELMAR NIKLAS; BIEHL, MARTIN; SCHULZ, JURGEN
To: MILTENYI BIOTEC GMBH
Reel/Frame 067836/0313 →
Continuity (10)
Continuation 18083279 · Dec 16, 2022
Continuation 17725509 · Apr 20, 2022
Continuation 16889471 · Jun 1, 2020
Continuation 16675072 · Nov 5, 2019
Continuation 15706517 · Sep 15, 2017
Continuation 15395215 · Dec 30, 2016
Continuation 14181023 · Feb 14, 2014
Division 12745688
Provisional Application 61012361 · Dec 7, 2007
Related Publication 20240219392A1 · Jul 4, 2024
References Cited (102)
US 3586413A · Adams · 1971 [cited by applicant]
US 3955755A · Breillatt, Jr. et al. · 1976 [cited by applicant]
US 4321330A · Baker et al. · 1982 [cited by applicant]
US 4632908A · Schultz et al. · 1986 [cited by applicant]
US 5260598A · Brass et al. · 1993 [cited by applicant]
US 5266476A · Sussman et al. · 1993 [cited by applicant]
US 5316667A · Brown et al. · 1994 [cited by applicant]
US 5691208A · Miltenyi et al. · 1997 [cited by applicant]
US 5904840A · Dibella · 1999 [cited by applicant]
US 6080581A · Anderson et al. · 2000 [cited by applicant]
US 6143508A · Okarma · 2000 [cited by applicant]
US 6709377B1 · Rochat et al. · 2004 [cited by applicant]
US 8727132B2 · Miltenyi et al. · 2014 [cited by applicant]
US 8747290B2 · Miltenyi et al. · 2014 [cited by applicant]
US 9625463B2 · Miltenyi et al. · 2017 [cited by applicant]
US 9714945B2 · Miltenyi et al. · 2017 [cited by applicant]
US 10119970B2 · Miltenyi et al. · 2018 [cited by applicant]
US 10350245B2 · Adair et al. · 2019 [cited by applicant]
US 10620212B2 · Miltenyi et al. · 2020 [cited by applicant]
US 10705090B2 · Miltenyi et al. · 2020 [cited by applicant]
US 10705091B2 · Miltenyi et al. · 2020 [cited by applicant]
US 11499976B2 · Miltenyi et al. · 2022 [cited by applicant]
US 11499977B2 · Miltenyi et al. · 2022 [cited by applicant]
US 11531031B2 · Miltenyi et al. · 2022 [cited by applicant]
US 20020144939A1 · Dolecek · 2002 [cited by applicant]
US 20020173034A1 · Barbera-Guillem et al. · 2002 [cited by applicant]
US 20030040104A1 · Barbera-Guillem · 2003 [cited by applicant]
US 20040209755A1 · Moore et al. · 2004 [cited by applicant]
US 20050051466A1 · Carter et al. · 2005 [cited by applicant]
US 20060240550A1 · Goodwin et al. · 2006 [cited by applicant]
US 20070102374A1 · Kolenbrander · 2007 [cited by applicant]
US 20100311559A1 · Miltenyi et al. · 2010 [cited by applicant]
US 20110003380A1 · Miltenyi et al. · 2011 [cited by applicant]
US 20140212961A1 · Miltenyi et al. · 2014 [cited by applicant]
US 20140370592A1 · Miltenyi et al. · 2014 [cited by applicant]
US 20160216270A1 · Miltenyi et al. · 2016 [cited by applicant]
US 20170107480A1 · Miltenyi et al. · 2017 [cited by applicant]
US 20180010087A1 · Miltenyi et al. · 2018 [cited by applicant]
US 20200071670A1 · Shi et al. · 2020 [cited by applicant]
US 20200208095A1 · Oram et al. · 2020 [cited by applicant]
US 20210403856A1 · Smith et al. · 2021 [cited by applicant]
DE 10127068A1 · 2002 [cited by applicant]
EP 16552A1 · 1980 [cited by applicant]
EP 535618A1 · 1993 [cited by applicant]
EP 654669A2 · 1995 [cited by applicant]
EP 2227334B1 · 2011 [cited by applicant]
WO 9004019A1 · 1990 [cited by applicant]
WO 02094351A2 · 2002 [cited by applicant]
WO 2009072003A2 · 2009 [cited by applicant]
WO 2009072003A3 · 2009 [cited by applicant]
“Now FDA Approved—The CliniMACS CD34 Reagent System”, Miltenyi Biotec, Available Online at: www.miltenyibiotec.com/en/clinicalapplications/lp_clinimacs_system_fda_slideraspx, Jan. 8, 2016, 2 pages. [cited by applicant]
“Product Guide for CliniMACS Prodigy System”, Miltenyi Biotec, Available Online at: www.miltenyibiotec.com/local, Jan. 8, 2016, 14 pages. [cited by applicant]
“Product Guide for the CliniMACS Prodigy”, Miltenyi Biotec, Available Online at: www.miltenyibiotec.com/loca, Jan. 8, 2016, 2 pages. [cited by applicant]
“The Next Step in Patient-Specific Cell Therapy Manufacturing”, Cocoon®, Lonza Pharma & Biotech, 2012, 9 pages. [cited by applicant]
“The Way to Integrated Cell Processing—25 Years of Development and Innovation at Miltenyi Biotec”, Miltenyi Biotec, vol. 16, Jan. 2014, 4 pages. [cited by applicant]
U.S. Appl. No. 12/745,688, Final Office Action, Mailed on Oct. 28, 2013, 9 pages. [cited by applicant]
U.S. Appl. No. 12/745,688, Non-Final Office Action, Mailed on Feb. 25, 2013, 10 pages. [cited by applicant]
U.S. Appl. No. 12/745,688, Notice of Allowance, Mailed on Mar. 20, 2014, 7 pages. [cited by applicant]
U.S. Appl. No. 12/745,688, “Restriction Requirement”, Oct. 3, 2012, 5 pages. [cited by applicant]
U.S. Appl. No. 12/745,689, Final Office Action, Mailed on Sep. 26, 2013, 13 Pages. [cited by applicant]
U.S. Appl. No. 12/745,689, Non-Final Office Action, Mailed on Jan. 28, 2013, 9 Pages. [cited by applicant]
U.S. Appl. No. 12/745,689, Notice of Allowance, Mailed on Jan. 31, 2014, 7 pages. [cited by applicant]
U.S. Appl. No. 14/181,023, Advisory Action, Mailed on Jun. 24, 2016, 3 pages. [cited by applicant]
U.S. Appl. No. 14/181,023, Final Office Action, Mailed on Feb. 26, 2016, 16 pages. [cited by applicant]
U.S. Appl. No. 14/181,023, Non-Final Office Action, Mailed on Jul. 9, 2015, 15 pages. [cited by applicant]
U.S. Appl. No. 14/181,023, Non-Final Office Action, Mailed on Oct. 21, 2016, 8 pages. [cited by applicant]
U.S. Appl. No. 14/181,023, Notice of Allowance, Mailed on Dec. 7, 2016, 8 pages. [cited by applicant]
U.S. Appl. No. 14/201,744, Non-Final Office Action, Mailed on Aug. 9, 2016, 15 pages. [cited by applicant]
U.S. Appl. No. 14/201,744, “Notice Of Allowance”, Mar. 22, 2017, 8 pages. [cited by applicant]
U.S. Appl. No. 15/003,069, Advisory Action, Mailed on Nov. 28, 2018, 6 pages. [cited by applicant]
U.S. Appl. No. 15/003,069, Final Office Action, Mailed on Jul. 11, 2018, 12 pages. [cited by applicant]
U.S. Appl. No. 15/003,069, First Action Interview Office Action Summary, Mailed on Jan. 4, 2018, 4 pages. [cited by applicant]
U.S. Appl. No. 15/003,069, First Action Interview Pilot Program Pre-Interview Communication, Mailed on Sep. 15, 2017, 4 pages. [cited by applicant]
U.S. Appl. No. 15/003,069, Non-Final Office Action, Mailed on Sep. 18, 2019, 16 pages. [cited by applicant]
U.S. Appl. No. 15/003,069, Notice of Allowance, Mailed on Mar. 19, 2020, 8 pages. [cited by applicant]
U.S. Appl. No. 15/395,215, First Action Interview Office Action Summary, Mailed on May 11, 2018, 8 pages. [cited by applicant]
U.S. Appl. No. 15/395,215, First Action Interview Pilot Program Pre-Interview Communication, Mailed on May 11, 2018, 3 pages. [cited by applicant]
U.S. Appl. No. 15/395,215, Notice of Allowance, Mailed on Jul. 11, 2018, 8 pages. [cited by applicant]
U.S. Appl. No. 15/706,517, Non-Final Office Action, Mailed on Sep. 12, 2019, 10 pages. [cited by applicant]
U.S. Appl. No. 15/706,517, Notice of Allowance, Mailed on Dec. 30, 2019, 8 pages. [cited by applicant]
U.S. Appl. No. 16/668,745, “U.S. Patent Application No.”, Amendment and Reply Under 37 C.F.R § 1.114, Oct. 1, 2021, 8 pages. [cited by applicant]
U.S. Appl. No. 16/675,072, First Action Interview Pilot Program Pre-Interview Communication, Mailed On Feb. 12, 2020, 3 pages. [cited by applicant]
U.S. Appl. No. 16/675,072, Notice of Allowance, Mailed on Apr. 23, 2020, 8 pages. [cited by applicant]
U.S. Appl. No. 16/889,471, Final Office Action, Mailed on May 5, 2022, 9 pages. [cited by applicant]
U.S. Appl. No. 16/889,471, Non-Final Office Action, Mailed on Nov. 23, 2021, 10 pages. [cited by applicant]
U.S. Appl. No. 16/889,471, Notice of Allowance, Mailed on Sep. 14, 2022, 8 pages. [cited by applicant]
U.S. Appl. No. 17/725,388, Non-Final Office Action, Mailed on Jun. 17, 2022, 10 pages. [cited by applicant]
U.S. Appl. No. 17/725,388, Notice of Allowance, Mailed on Sep. 28, 2022, 8 pages. [cited by applicant]
U.S. Appl. No. 17/725,509, Non-Final Office Action, Mailed on Aug. 12, 2022, 10 pages. [cited by applicant]
U.S. Appl. No. 17/725,509, Notice of Allowance, Mailed on Sep. 28, 2022, 8 pages. [cited by applicant]
U.S. Appl. No. 18/083,279, Final Office Action, Mailed on Aug. 24, 2023, 9 pages. [cited by applicant]
U.S. Appl. No. 18/083,279, Non-Final Office Action, Mailed on May 12, 2023, 15 pages. [cited by applicant]
U.S. Appl. No. 18/083,279, Notice of Allowance, Mailed on Nov. 14, 2023, 9 pages. [cited by applicant]
Application No. EP11193362.8, European Search Report and Written Opinion, Mailed on Jul. 26, 2013, 8 pages. [cited by applicant]
Application No. EP12178904.4, European Search Report and Written Opinion, Mailed on Jul. 16, 2013, 5 pages. [cited by applicant]
Granzin et al., “Fully Automated Expansion and Activation of Clinical-Grade Natural Killer Cells for Adoptive Immunotherapy”, Cytotherapy, vol. 17, Mar. 2015, pp. 621-632. [cited by applicant]
Kumaresan et al., “Automating the Manufacture of Clinically Appealing Designer T Cell”, Treatment Strategies, Blood & Marrow Transplantation, vol. 1, Issue 1, May 2014, 7 pages. [cited by applicant]
Application No. PCT/IB2008/003823, International Preliminary Report on Patentability, Mailed on Jun. 8, 2010, 10 pages. [cited by applicant]
Application No. PCT/IB2008/003823, International Search Report and Written Opinion, Mailed on Jul. 30, 2009, 14 pages. [cited by applicant]
PCT/IB2008/003845, “International Search Report”, Jun. 26, 2009, 2 pages. [cited by applicant]
Spohn et al., “Automated CD34+ Cell Isolation of Peripheral Blood Stem Cell Apheresis Product”, Cytotherapy, vol. 17, Oct. 2015, pp. 1465-1471. [cited by applicant]
Sugai, “Fresenius AS.TEC204 Blood Bell Separator”, Therapeutic Apheresis and Dialysis, vol. 7, No. 1, Feb. 2003, pp. 37-43. [cited by applicant]